Loading...
HUTCHMED (China) Community
AIM:HCM Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
Community Investing Ideas
Growing Aging Populations Will Expand Oncology Pipeline Despite Regulatory Hurdles
Key Takeaways Strength in accelerated drug approvals and strong global uptake is set to expand revenue faster than forecasts, reinforced by proprietary platform and clinical advances. Increased commercialization, strategic flexibility, and demographic trends in core markets position the company for sustained sales growth and improved profitability.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
UK£5.5
60.2% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
24.41% p.a.
Profit Margin
9.59%
Future PE
71.26x
Share price in 2028
UK£6.7
China And Japan Oncology Markets Will Broaden Opportunity Amidst Headwinds
Key Takeaways New product launches, expanded indications, and global growth are expected to drive significant revenue gains, leveraging increased healthcare demand and broader reimbursement. Strategic investments, innovative R&D, and recovery in China sales position the company for stronger margins and more stable long-term earnings growth.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
UK£3.62
39.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
16.28% p.a.
Profit Margin
15.56%
Future PE
26.14x
Share price in 2028
UK£3.28